Biologics CDMO Market Poised to Hit $41.53 Billion by 2029 with Accelerating Growth Trends

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Biologics CDMO Market Size Growth Forecast: What to Expect by 2025?
The market size of biologics CDMO has seen a swift escalation in the past few years. It is projected to expand from $21.3 billion in 2024 to a whopping $24.15 billion in 2025, with a compound annual growth rate (CAGR) of 13.4%. The facets contributing to this growth over the historic period encompass enhanced development in biologics, cost-effectiveness along with adaptability, emphasis on vital competencies, compliance with regulatory standards, assurance of quality, and the worldwide expansion of pharmaceutical supply chains.

How Will the Biologics CDMO Market Size Evolve and Grow by 2029?
The biologics CDMO market is predicted to experience quick expansion in the approaching years, reaching a valuation of $41.53 billion by 2029, at a compound annual growth rate (CAGR) of 14.5%. This surge during the forecast period can be linked to factors such as growing need for biologic therapies, the rise of biosimilars and biobetters, increased investment in biomanufacturing infrastructure, a shift towards outsourcing complex procedures, focus on enhancing supply chain resilience and risk mitigation, regulatory harmonization, and speedy approvals. Key trends during this timeline involve capacity expansion for all-inclusive solutions, adoption of single-use technologies, assimilation of continuous manufacturing processes, and the rise of specialized CDMOs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

What Drivers Are Propelling the Growth of Biologics CDMO Market Forward?
The anticipated rise in demand for cell and genetic therapeutics is predicted to propel the expansion of the biologic CDMO market. Cell and gene therapies are innovative medical methodologies that use living cells or genetic substances to confront the root causes of diseases on the cell or genetic level. They provide potential solutions for conditions that are complex to treat or incurable through conventional pharmaceuticals. There is a rising demand for these cellular and genetic therapies mainly due to their potential to introduce groundbreaking treatment options for diseases by combating the underlying genetic or cellular causes. Biologic CDMOs aid in this process by providing knowledge in managing living cells, viral vectors, and genetic substances, which paves the way for a safe and efficient manufacturing of cell and gene therapies. They also assist biopharmaceutical firms in circumventing regulatory stipulations and technical hurdles, thereby making the progression from research to clinical applications smoother. For instance, in January 2023, The American Society of Gene & Cell Therapy (ASGCT), a foremost professional membership firm in the US, reported that the gene, cell, and RNA therapy pipeline saw a 7% expansion in 2022, reaching a cumulative of 3,726 therapies in development. Among these, 55% are gene therapies, whilst 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Consequently, the anticipated rise in demand for cell and genetic therapeutics is accelerating the expansion of the biologic CDMO market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Biologics CDMO Market?
Leading businesses in the biologics CDMO marketplace are introducing revolutionary tech-based options, including novel cell lines, to advance and augment the efficacy and capabilities of biopharmaceutical production. These advancements have boosted the development of therapeutic antibodies displaying increased effectiveness, thereby tackling the issues related to immunotherapy research. For instance, in November 2023, the Swiss firm Lonza Group known for its expertise in pharmaceutical and biotechnology manufacturing, unveiled their 'GS Effex' cell lines. These are designed to create antibodies that are completely devoid of Fucose - a form of sugar, assisting in enhancing potency without any trade-off on other operational attributes. This technology is instrumental in addressing the hurdles associated with immunotherapy R&D that require an upsurge in antibody therapeutic potency. The GS Effex cell line is a robust, scalable solution boosting therapeutic development from the stage of discovery to commercial production.

What Are the Key Segments in the Biologics CDMO Market?
The biologics cdmo market covered in this report is segmented -

1) By Cell Type: Mammalian, Non-Mammalian
2) By Product Type: Biologics, Biosimilars

Subsegments:
1) By Mammalian: Chinese Hamster ovary* (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells
2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

Who Are the Key Players Shaping the Biologics CDMO Market's Competitive Landscape?
Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

What Geographic Markets Are Powering Growth in the Biologics CDMO Market?
North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14056

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.